Clinical trials: Sezary Syndrome
Mycosis Fungoides, Mycosis Fungoides/Sezary Syndrome
Pembrolizumab in Combination With Gemcitabine in People With Advanced Mycosis Fungoides or Sézary Syndrome
The purpose of this study is to find out whether the combination of pembrolizumab and gemcitabine is an effective treatment for mycosis fungoides and Sézary syndrome.
- Conditions
- Mycosis Fungoides, Mycosis Fungoides/Sezary Syndrome, Sezary Syndrome, Sézary
- Trial name
- NCT04960618
- Testing
- Gemcitabine, Pembrolizumab
- Where
- 8 sites in United States
- Volunteers
- 14 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Chronic Myeloproliferative Disorders, Graft Versus Host Disease
Donor Peripheral Stem Cell Transplant in Treating Patients With Advanced Hematologic Cancer or Other Disorders
RATIONALE: Giving chemotherapy and total-body irradiation before a donor peripheral stem cell transplant helps stop the growth of cancer or abnormal cells.
- Conditions
- Chronic Myeloproliferative Disorders, Graft Versus Host Disease, Leukemia, Lymphoma
- Trial name
- NCT00544115
- Testing
- busulfan, cyclophosphamide, cyclosporine
- Volunteers
- 260 people
- Sponsor
- City of Hope Medical Center
Cutaneous T Cell Lymphoma, Cutaneous T-Cell Lymphoma/Mycosis Fungoides
Real World Experience With Mogamulizumab in the Treatment of Cutaneous T-cell Lymphoma
This study is designed to describe the clinical activity and safety profile of mogamulizumab at standard dose in the treatment of CTCL patients in real world setting
- Conditions
- Cutaneous T Cell Lymphoma, Cutaneous T-Cell Lymphoma/Mycosis Fungoides, Cutaneous T-Cell Lymphoma/Sezary Syndrome
- Trial name
- FIL_MOGA (NCT06113081)
- Where
- 21 sites in Italy
- Volunteers
- 100 people
- Sponsor
- Fondazione Italiana Linfomi - ETS
T-cell Lymphoma, NK-Cell Lymphoma
A Registry for People With T-cell Lymphoma
The purpose of this registry study is to create a database-a collection of information-for better understanding T-cell lymphoma.
- Conditions
- T-cell Lymphoma, NK-Cell Lymphoma, T-cell Prolymphocytic Leukemia, T-cell Large Granular Lymphocytic Leukemia
- Trial name
- NCT05978141
- Testing
- Optional Blood Sample and Nail Sample
- Where
- 26 sites in United States
- Volunteers
- 1,000 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Cutaneous T Cell Lymphoma, Fungoides Mycosis Sezary Syndrome
Pembrolizumab and Mogamulizumab in Advanced-stage, Relapsed/Refractory Cutaneous T-cell Lymphomas
This is an open-label, single-arm, multicenter, phase II study combining pembrolizumab and mogamulizumab in patients with advanced-stage, relapsed or refractory CTCL Each cycle will equal 6 weeks.
- Trial name
- NCT05956041
- Testing
- Pembrolizumab, Mogamulizumab
- Where
- United States
- Volunteers
- 23 people
- Sponsor
- University of Michigan Rogel Cancer Center
Lymphoma, T-Cell, Lymphoma, T-Cell, Cutaneous
IPH4102/Lacutamab Alone or in Combination With Chemotherapy in Patients With Advanced T Cell Lymphoma
This is an open label, multi-cohort, and multi-center phase II study, which evaluates the clinical activity and safety of IPH4102 in Sezary Syndrome and Mycosis fungoides as single agent.
- Conditions
- Lymphoma, T-Cell, Lymphoma, T-Cell, Cutaneous, Mycosis Fungoides/Sezary Syndrome
- Trial name
- TELLOMAK (NCT03902184)
- Testing
- IPH4102
- Where
- 53 sites in United States, Austria and 6 more
- Volunteers
- 170 people
- Sponsor
- Innate Pharma
Cutaneous T-Cell Lymphoma Refractory, Cutaneous T-Cell Lymphoma, Relapsed
Aclarubicin Plus Cyclophosphamide, Vincristine, and Prednisone (CAOP) in Patients With Previously Treated Cutaneous T-cell Lymphoma
Cutaneous T-cell lymphomas (CTCL) are a rare and heterogeneous group of extranidal T-cell lymphomas characterized by skin involvement. Current treatment options for CTCL are limited.
- Conditions
- Cutaneous T-Cell Lymphoma Refractory, Cutaneous T-Cell Lymphoma, Relapsed, Sezary Syndrome, Cutaneous T Cell Lymphoma (CTCL)
- Trial name
- NCT07535710
- Testing
- Aclarubicin, Cyclophosphamide, Vincristine
- Where
- 2 sites in China
- Volunteers
- 37 people
- Sponsor
- Shanghai Jiao Tong University School of Medicine
Adult Acute Lymphoblastic Leukemia in Remission, Adult Acute Myeloid Leukemia in Remission
A Two-Step Approach to Reduced Intensity Bone Marrow Transplant for Patients With Hematological Malignancies
This phase II trial studies how well reduced intensity donor stem cell transplant works in treating patients with hematologic malignancies.
- Conditions
- Adult Acute Lymphoblastic Leukemia in Remission, Adult Acute Myeloid Leukemia in Remission, Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities, Adult Acute Myeloid Leukemia With Del(5q)
- Trial name
- NCT01384513
- Testing
- Fludarabine, Busulfan, Total Body Irradiation (TBI)
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University
Mycosis Fungoides, Lymphomatoid Papulosis
Dosing of Brentuximab Vedotin for Mycosis Fungoides, Sezary Syndrome Patients
The purpose of this study is to test any good and bad effects of the study drug called brentuximab vedotin at a lower dose than is FDA-approved.
- Conditions
- Mycosis Fungoides, Lymphomatoid Papulosis, Sezary Syndrome
- Trial name
- NCT03587844
- Testing
- brentuximab vedotin
- Where
- 8 sites in United States
- Volunteers
- 58 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Sezary Syndrome, Ichthyosis, Lamellar
Lymphocyte Phenotype of Autosomal Recessive Congenital Ichthyoses Mutated NIPAL4 (Nipal4-nEDD)
Autosomal recessive congenital ichthyoses (ARCI) are monogenic diseases of cornification that correspond to a diffuse abnormality (affecting the entire integument) of epidermal differentiation and therefore of the skin barrier.
- Trial name
- NIPALYMPHO (NCT07477769)
- Testing
- blood sampling
- Volunteers
- 10 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Cutaneous T-cell Lymphoma, Sezary Syndrome
Blood, Urine, and Tissue Collection for Cutaneous Lymphoma, Eczema, and Atopic Dermatitis Research
This is a tissue, urine, and blood banking protocol for cutaneous t-cell lymphoma (CTCL), eczema, and atopic dermatitis patients for current and future research.
- Conditions
- Cutaneous T-cell Lymphoma, Sezary Syndrome, Mycosis Fungoides, Eczema
- Trial name
- NCT00177268
- Testing
- Blood draw, skin biopsy or urine collection
- Where
- United States
- Volunteers
- 200 people
- Sponsor
- University of Pittsburgh
Sezary Syndrome
Extracorporeal Photopheresis in Sezary Syndrome
The primary endpoint is to determine if ECP induces a decrease in % of tumor cells after treatment. 20 patients with Sezary Syndrome will receive ECP weekly x4, then bi-weekly for 5 months.
- Trial name
- ECP (NCT05157581)
- Testing
- Extracorporeal photopheresis (ECP), Methoxsalen Injection
- Where
- 3 sites in United States
- Volunteers
- 20 people
- Sponsor
- Oleg E. Akilov, MD, PhD
Cutaneous T Cell Lymphoma, Cutaneous T-Cell Lymphoma/Mycosis Fungoides
Systemic Therapies in the Treatment of Cutaneous T-cell Lymphoma
The study is designed to describe the different approaches of systemic therapies for the treatment of Cutaneous T-cell Lymphoma in real world setting.
- Conditions
- Cutaneous T Cell Lymphoma, Cutaneous T-Cell Lymphoma/Mycosis Fungoides, Cutaneous T-Cell Lymphoma/Sezary Syndrome
- Trial name
- FIL_CTCL (NCT06588868)
- Where
- 18 sites in Italy
- Volunteers
- 400 people
- Sponsor
- Fondazione Italiana Linfomi - ETS
Lymphoma, T-Cell, Cutaneous, Lymphomatoid Papulosis
Tissue Repository: CTCL Collection Protocol
This document is a protocol for a non-interventional human research study in which the investigator hopes to better understand the changes that take place in T cells in Cutaneous T-cell lymphoma (CTCL).
- Conditions
- Lymphoma, T-Cell, Cutaneous, Lymphomatoid Papulosis, Sézary Syndrome
- Trial name
- NCT02840747
- Where
- United States
- Volunteers
- 400 people, healthy volunteers welcome
- Sponsor
- Columbia University
Chronic Myeloproliferative Disorders, Leukemia
Tissue, Blood, and Body Fluid Sample Collection From Patients With Hematologic Cancer
RATIONALE: Collecting and storing samples of tissue, blood, and body fluid from patients with cancer to study in the laboratory may help the study of cancer in the future.
- Conditions
- Chronic Myeloproliferative Disorders, Leukemia, Lymphoma, Lymphoproliferative Disorder
- Trial name
- NCT01137643
- Testing
- biologic sample preservation procedure, cytology specimen collection procedure
- Where
- United States
- Volunteers
- 15,000 people
- Sponsor
- UNC Lineberger Comprehensive Cancer Center
Mycosis Fungoides, Recurrent Mycosis Fungoides
Testing the Addition of an Anti-cancer Drug, Hu5F9-G4 (Magrolimab), to the Usual Chemotherapy Treatment (Mogamulizumab) in T-Cell (a Type of Immune Cell) Lymphoma That Has Returned After Treatment or Does Not Respond to Treatment
This phase Ib/II trial identifies the best dose and possible benefits and/or side effects of magrolimab when given in combination with mogamulizumab in treating patients with stage IB-IV mycosis fungoides or Sezary syndrome types…
- Conditions
- Mycosis Fungoides, Recurrent Mycosis Fungoides, Recurrent Mycosis Fungoides and Sezary Syndrome, Recurrent Sezary Syndrome
- Trial name
- NCT04541017
- Testing
- Biospecimen Collection, Computed Tomography, Magrolimab
- Where
- 18 sites in United States
- Volunteers
- 8 people
- Sponsor
- National Cancer Institute (NCI)
Cutaneous T Cell Lymphoma (CTCL), Mycosis Fungoides
A Phase 1, Multicenter, Open-label, Prospective, First-in-human Dose-escalation Clinical Trial of Domain Therapeutics' Anti-CCR8 Monoclonal Antibody (DT-7012) in Patients With Relapsed or Refractory Cutaneous T-cell Lymphomas (CTCL)
Cutaneous T-cell lymphomas (CTCL) are a heterogeneous group of lymphomas characterized by a primary involvement of the skin. Among them, mycosis fungoides (MF) and Sézary syndrome (SS) are the most common subtypes.
- Conditions
- Cutaneous T Cell Lymphoma (CTCL), Mycosis Fungoides, Sezary Syndrome
- Trial name
- CITY (NCT07213882)
- Testing
- DT-7012
- Volunteers
- 30 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Mycosis Fungoides, Sezary Syndrome
Assessment of Safety and Efficacy of Poteligeo Inj. 20 mg (Mogamulizumab) Through Use-result Surveillance
The purpose of this surveillance is to assess the safety and efficacy of Poteligeo Inj. 20 mg (mogamulizumab) in routine clinical settings.
- Trial name
- NCT07132567
- Testing
- Poteligeo 20mg
- Where
- 6 sites in South Korea
- Volunteers
- 15 people
- Sponsor
- Kyowa Kirin Co., Ltd.
Mycosis Fungoides, Sezary Syndrome
Pembrolizumab in Treating Patients With Stage IB-IV Mycosis Fungoides
This phase II trial studies how well pembrolizumab works in treating patients with stage IB-IV mycosis fungoides. Immunotherapy with monoclonal antibodies, such as pembrolizumab, may help the body's immune system attack the…
- Conditions
- Mycosis Fungoides, Sezary Syndrome, Stage IB Mycosis Fungoides and Sezary Syndrome AJCC v8, Stage II Mycosis Fungoides and Sezary Syndrome AJCC v8
- Trial name
- NCT03695471
- Testing
- Pembrolizumab
- Where
- United States
- Volunteers
- 9 people
- Sponsor
- Mayo Clinic
CTCL, Mycosis Fungoides
Ritlecitinib in CTCL
The purpose of this research study is to evaluate the effectiveness and safety of Ritlecitinib in skin and blood in persons with Cutaneous T-Cell Lymphoma (CTCL).
- Conditions
- CTCL, Mycosis Fungoides, Sezary Syndrome
- Trial name
- NCT05879458
- Testing
- Ritlecitinib
- Where
- United States
- Volunteers
- 7 people
- Sponsor
- Icahn School of Medicine at Mount Sinai